Mika Scheinin

19.6k total citations · 2 hit papers
389 papers, 15.3k citations indexed

About

Mika Scheinin is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Anesthesiology and Pain Medicine. According to data from OpenAlex, Mika Scheinin has authored 389 papers receiving a total of 15.3k indexed citations (citations by other indexed papers that have themselves been cited), including 143 papers in Molecular Biology, 112 papers in Cellular and Molecular Neuroscience and 93 papers in Anesthesiology and Pain Medicine. Recurrent topics in Mika Scheinin's work include Receptor Mechanisms and Signaling (126 papers), Anesthesia and Sedative Agents (90 papers) and Neuroscience and Neuropharmacology Research (65 papers). Mika Scheinin is often cited by papers focused on Receptor Mechanisms and Signaling (126 papers), Anesthesia and Sedative Agents (90 papers) and Neuroscience and Neuropharmacology Research (65 papers). Mika Scheinin collaborates with scholars based in Finland, United States and United Kingdom. Mika Scheinin's co-authors include Ewen MacDonald, Harry Scheinin, Brian K. Kobilka, M. Linnoila, Riku Aantaa, Frederick K. Goodwin, Jukka Sallinen, Ranan Rimón, Matti Virkkunen and A Nuutila and has published in prestigious journals such as Science, Journal of Biological Chemistry and Circulation.

In The Last Decade

Mika Scheinin

384 papers receiving 14.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from nonimpulsive violent behavior

1983 1.0k citations Mika Scheinin et al. profile →
Different Metabolic Responses of Human Brown Adipose Tissue to Activation by Cold and Insulin

2011 581 citations Pirjo Nuutila, Vesa Oikonen et al. profile →

Peers

Countries citing papers authored by Mika Scheinin

Since Specialization

Citations

This map shows the geographic impact of Mika Scheinin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mika Scheinin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mika Scheinin more than expected).

Fields of papers citing papers by Mika Scheinin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mika Scheinin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mika Scheinin. The network helps show where Mika Scheinin may publish in the future.

Co-authorship network of co-authors of Mika Scheinin

This figure shows the co-authorship network connecting the top 25 collaborators of Mika Scheinin. A scholar is included among the top collaborators of Mika Scheinin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mika Scheinin. Mika Scheinin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase 1b trial on the safety, tolerability and immunogenicity of anti‐amyloid vaccine ALZ‐101 in subjects with MCI or mild AD 2024 ·Alzheimer s & Dementia ·Henrik Zetterberg, Juha O. Rinne, Anders Sandberg, (unknown), Mika Scheinin, Stefan Pierrou, (unknown)	2
2	Safety, tolerability and immunogenicity of PRV-101, a multivalent vaccine targeting coxsackie B viruses (CVBs) associated with type 1 diabetes: a double-blind randomised placebo-controlled Phase I trial 2024 ·Diabetologia ·Heikki Hyöty, (unknown), Jutta E. Laiho, Gail M. Comer, Wei Tian, Taina Härkönen, (unknown), Sami Oikarinen, Leena Puustinen, (unknown), Francisco León, Mika Scheinin, Mikael Knip, Miguel A. F. Sanjuán	11
3	Uptake of ¹⁸ F-rhPSMA-7.3 in Positron Emission Tomography Imaging of Prostate Cancer: A Phase 1 Proof-of-Concept Study 2021 ·Cancer Biotherapy and Radiopharmaceuticals ·Simona Malaspina, Pekka Taimen, Markku Kallajoki, Vesa Oikonen, Anna Kuisma, Otto Ettala, Kalle Mattila, Peter J. Boström, Heikki Minn, Kari K. Kalliokoski, Ernst J. Postema, Matthew P. Miller, Mika Scheinin	6
4	Candida antarctica Lipase A-Based Enantiorecognition of a Highly Strained 4-Dibenzocyclooctynol (DIBO) Used for PET Imaging 2020 ·Molecules ·(unknown), Käthe M. Dahlström, Rakesh Puttreddy, Kari Rissanen, Tiina A. Salminen, Mika Scheinin, Xiang‐Guo Li, Arto Liljeblad	3
5	Assessing an Electronic Health Record research platform for identification of clinical trial participants 2020 ·Contemporary Clinical Trials Communications ·(unknown), (unknown), (unknown), Antti Palomäki, Tuija Vasankari, Juhani Airaksinen, Risto Huupponen, Mika Scheinin, Juuso Blomster	4
6	Evidence that the multiflorine‐derived substituted quinazolidine 55P0251 augments insulin secretion and lowers blood glucose via antagonism at α ₂ ‐adrenoceptors in mice 2019 ·Diabetes Obesity and Metabolism ·(unknown), (unknown), Barbara Brunmair, Immanuel Adorjan, Miroslav Genov, Alexandra Kautzky‐Willer, Thomas Scherer, Mika Scheinin, (unknown), Clemens Fürnsinn	4
7	Effects of vatinoxan on cardiorespiratory function, fecal output and plasma drug concentrations in horses anesthetized with isoflurane and infusion of medetomidine 2019 ·The Veterinary Journal ·(unknown), Marja Raekallio, Anna Mykkänen, (unknown), Mika Scheinin, Heidi Hautajärvi, Sofia Männikkö, Outi Vainio	3
8	Effects of vatinoxan on cardiorespiratory function and gastrointestinal motility during constant‐rate medetomidine infusion in standing horses 2019 ·Equine Veterinary Journal ·(unknown), Marja Raekallio, Anna Mykkänen, Sofia Männikkö, Mika Scheinin, Rachel Bennett, Outi Vainio	12
9	Treating gambling disorder with as needed administration of intranasal naloxone: a pilot study to evaluate acceptability, feasibility and outcomes 2019 ·BMJ Open ·Sari Castrén, (unknown), (unknown), Anne H. Salonen, (unknown), Mika Scheinin, Hannu Alho	4
10	Sublingual administration of detomidine to calves prior to disbudding: a comparison with the intravenous route 2014 ·Veterinary Anaesthesia and Analgesia ·(unknown), Marja Raekallio, (unknown), Laura Hänninen, (unknown), Marianna Norring, Satu Raussi, Valtteri Rinne, Mika Scheinin, Outi Vainio	9
11	3-[(Imidazolidin-2-yl)imino]indazole ligands with selectivity for the α2-adrenoceptor compared to the imidazoline I1 receptor 2010 ·Bioorganic & Medicinal Chemistry ·Franciszek Sączewski, Anita Kornicka, Alan L. Hudson, (unknown), Mika Scheinin, (unknown), (unknown), (unknown), (unknown), М. Gdaniec	19
12	Reproducibility of automated simplified voxel-based analysis of PET amyloid ligand [11C]PIB uptake using 30-min scanning data 2009 ·European Journal of Nuclear Medicine and Molecular Imaging ·Sargo Aalto, Noora M. Scheinin, Nina Kemppainen, Kjell Någren, Marita Kailajärvi, Mika Leinonen, Mika Scheinin, Juha O. Rinne	24
13	Trimetazidine, a Metabolic Modulator, Has Cardiac and Extracardiac Benefits in Idiopathic Dilated Cardiomyopathy 2008 ·Circulation ·Helena Tuunanen, Erik Engblom, Athanasios S. Naum, Kjell Någren, Mika Scheinin, Birger Hesse, Juhani Airaksinen, Pirjo Nuutila, Patricia Iozzo, Heikki Ukkonen, Lionel H. Opie, Juhani Knuuti	186
14	Pharmacokinetics of intravenous dexmedetomidine in children under 11 yr of age 2008 ·British Journal of Anaesthesia ·Sanna Vilo, Paula Rautiainen, Kaike K. Kaisti, Riku Aantaa, Mika Scheinin, Tuula Manner, Klaus T. Olkkola	88
15	The second extracellular loop of α_2A‐adrenoceptors contributes to the binding of yohimbine analogues 2007 ·British Journal of Pharmacology ·(unknown), Henri Xhaard, Jori O. Ruuskanen, (unknown), Hasse Karlsson, Mark S. Johnson, Mika Scheinin	22
16	Identification of Duplicated Fourth α2-Adrenergic Receptor Subtype by Cloning and Mapping of Five Receptor Genes in Zebrafish 2004 ·Molecular Biology and Evolution ·Jori O. Ruuskanen, Henri Xhaard, Anne Marjamäki, Erik Salaneck, Tiina A. Salminen, Yi‐Lin Yan, John H. Postlethwait, Mark S. Johnson, Dan Larhammar, Mika Scheinin	59
17	Nonradioactive GTP Binding Assay to Monitor Activation of G Protein-Coupled Receptors 2003 ·Assay and Drug Development Technologies ·(unknown), Veli-Matti Mukkala, (unknown), (unknown), Pertti Hurskainen, Mika Scheinin, Ilkka Hemmilä	47
18	A Comparison of Gasless Mechanical and Conventional Carbon Dioxide Pneumoperitoneum Methods for Laparoscopic Cholecystectomy 1998 ·Anesthesia & Analgesia ·Anna‐Maria Koivusalo, Ilmo Kellokumpu, Mika Scheinin, Ilkka Tikkanen, Heikki Mäkisalo, L. Lindgren	59
19	Acute effects of medetomidine, a selective α2-adrenoceptor agonist, on anterior pituitary hormone and cortisol secretion in man 1988 ·European Journal of Endocrinology ·Antero Kallio, Markku Koulu, Harry Scheinin, Jorma Viikari, Mika Scheinin	20
20	Monoamine metabolites in human cerebrospinal fluid: indicators of neuronal activity? 1985 ·PubMed ·Mika Scheinin	44

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact